share_log

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary

Evogene Ltd. (EVGN) 2024年第三季度業績會議 轉錄摘要
moomoo AI ·  13:56  · 電話會議

The following is a summary of the Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript:

以下是Evogene Ltd.(EVGN)2024年第三季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Evogene reported Q3 2024 revenues of approximately $1.8 million, a decrease from Q3 2023's $3.8 million, primarily due to a decrease in licensing revenue from Lavie Bio.

  • The company recorded an operating loss of approximately $17.6 million in the first nine months of 2024, slightly improved from $18.9 million in the same period of 2023.

  • Financing expenses for the first nine months of 2024 were approximately $0.38 million, a shift from a financing income of $2.3 million in the first nine months of 2023.

  • Projected cash usage for 2024 is approximately $8 million to $10 million, a decrease from $12.5 million in 2023, following a reduction in workforce by 16% and other expense management strategies.

  • Evogene報告稱,2024年第三季度收入約爲180萬美元,低於2023年第三季度的380萬美元,這主要是由於Lavie Bio的許可收入減少。

  • 該公司在2024年前九個月錄得約1760萬美元的營業虧損,較2023年同期的1,890萬美元略有改善。

  • 2024年前九個月的融資支出約爲38萬美元,與2023年前九個月的230萬美元融資收入有所不同。

  • 在員工裁員16%和其他費用管理策略之後,2024年的預計現金使用量約爲800萬至1000萬美元,較2023年的1,250萬美元有所減少。

Business Progress:

業務進展:

  • Evogene highlighted significant progress in seed production infrastructure notably in Kenya and Brazil for its subsidiary Casterra, which will support existing and future seed demands.

  • Lavie Bio announced the expansion of its bio-inoculant product, Yalos, to winter wheat and soybeans, and advancement of its bio-fungicide LAV321.

  • The company announced a collaboration with Google Cloud to develop a generative AI model for novel small molecule design, leveraging Evogene's AI tech engines.

  • Evogene強調了其子公司Casterra在種子生產基礎設施方面的重大進展,特別是在肯尼亞和巴西,這將支持現有和未來的種子需求。

  • Lavie Bio宣佈將其生物接種劑產品Yalos擴展到冬小麥和大豆,並推進其生物殺菌劑 LAV321。

  • 該公司宣佈與谷歌雲合作,利用Evogene的人工智能技術引擎,爲新的小分子設計開發生成式人工智能模型。

Opportunities:

機會:

  • Continued revenue growth anticipated for 2024, driven by existing seed orders from Casterra and new product launches from Lavie Bio.

  • Expansion into bioinformatics through collaboration with Google Cloud, positioning its AI tech engines at the forefront of novel molecule design.

  • 受Casterra現有種子訂單和Lavie Bio新產品推出的推動,預計2024年的收入將持續增長。

  • 通過與谷歌雲的合作擴展到生物信息學,將其人工智能技術引擎置於新分子設計的最前沿。

Risks:

風險:

  • Fluctuations in operating expenses and increased financial expenses related to warrants issued during fundraising could impact financial stability.

  • 運營費用的波動以及與籌款期間發行的認股權證相關的財務支出增加可能會影響財務穩定。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論